Latent reservoirs of HIV infection: Flushing with IL-2?

Nature Medicine

Volumn 5, Issue 6, 1999, Pages 611-612

  Cooper, David A ^a   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY; VIRUS RNA;

CELL PROLIFERATION; CYTOPATHOGENIC EFFECT; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROVIRUS; SHORT SURVEY; VIREMIA; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032999329     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/9454     Document Type: Short Survey

References (13)

1. Wei, X., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
2. Ho, D.D., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
3. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV and guidelines for the use of antiretroviral agents in adults and adolescents. Morb. Mort. Weekly Report 47, 1-83 (1998).
4. Carpenter, C.C.J. et al. Antiretroviral therapy for HIV infection in 1997:updated recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 277, 1962-1969 (1997).
5. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Med. 5, 651-655 (1999).
6. Kovacs, J.A. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med.335, 1350-1356 (1996).
7. Carr, A. et al. Outpatient continuous Intravenous interleukin-2 or subcutaneous, polyethylene glycol modified interleukin-2 in human immunodeficiency virus-infected patients: a randomised, controlled, multicenter study. J. Infect. Dis. 178, 992-999 (1998).
8. Davey, R.T. et al. Sub-cutaneous administration of interleukin-2 in human immnuodeficiency virus type 1-infected persons. J. Infect. Dis. 175, 781-789 (1997).
9. Chun, T.-W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
10. th Conference on Human Retroviruses and Opportunistic Infections abstract LB6 (Chicago, Illinois, Feb 1999).
11. Natarjan, V. et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 353, 119-120 (1999).
12. Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
13. Cooper, D.A. & Emery, S. Therapeutic strategies for HIV infection - time to think hard. N. Engl. J. Med. 339, 1319-1320 (1998).